Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
 
Approvals Action
Pfizer antibiotic sees first generic
Southern Cross has added the first copy of a Pfizer antibiotic to the ARTG in a week which saw a flurry of generic activity.
Pipeline Monitor
Lilly, Amgen rev up major drugs
Lilly's Taltz and Amgen's Repatha both won significant extensions from the FDA this week as the companies attempt to build blockbuster futures out of their pipelines.
Perspective
Big city moves not just about the view
Moves by pharma companies to leave suburban sites for slick new city offices is as much about how they want to be seen as it is about the scenery.